Back to top

Analyst Blog

Seattle Genetics, Inc. (SGEN - Snapshot Report) recently commenced a phase I/II study to evaluate Adcetris in combination with Teva Pharmaceutical Industries Ltd.’s (TEVA - Analyst Report) Treanda (bendamustine) for Hodgkin lymphoma (HL) patients after first relapse.

The single-arm, open-label study is divided into two cohorts. The phase I cohort’s primary endpoint is to find the recommended dosing level of Treanda in combination with Adcetris and evaluate the safety and tolerability of this combination.

The complete remission rate will be assessed as the primary endpoint of the phase II cohort. Secondary endpoints include best response, duration of response and progression-free survival.

After receiving Adcetris plus Treanda patients will have an option to suspend the therapy and undergo an autologous stem cell transplant (ASCT) following which treatment with single-agent Adcetris will be resumed.

Seattle Genetics also announced that Adcetris data on first line salvage therapy in relapsed/refractory HL was presented recently. In this study, 85.7% of the patients showed an objective response rate.

In May 2013, the US Food and Drug Administration (FDA) accepted a supplemental biologics license application (sBLA) for Adcetris for retreatment and extended duration of medication with the drug beyond 16 cycles in relapsed HL and systemic anaplastic large cell lymphoma (sALCL).

We note that Adcetris was approved by the FDA in Aug 2011 for the treatment of patients with HL after failure of ASCT or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not suitable for ASCT. Adcetris was also approved for sALCL in treatment-experienced patients.

Seattle Genetics carries a Zacks Rank #3 (Hold). Right now, Anika Therapeutics Inc. and Myriad Genetics Inc. (MYGN - Analyst Report) look more attractive with a Zacks Rank #1 (Strong Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
STRATTEC SE… STRT 85.29 +6.29%
SUPER MICRO… SMCI 26.03 +6.29%
CENTURY ALU… CENX 26.25 +5.08%
TESLA MOTOR… TSLA 278.27 +3.18%
BAIDU ADS BIDU 220.85 +2.95%